Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: Outcomes of an expanded access program

Clinical Lung Cancer

Volumn 7, Issue 1, 2005, Pages 40-46

  Jänne, Pasi A ^a   Wozniak, Antoinette J ^b   Belani, Chandra P ^c   Keohan, Mary Louise ^d   Ross, Helen J ^e   Polikoff, Jonathan A ^f   Mintzer, David M ^g   Taylor, Loretta ^h   Ashland, Joseph ^h   Ye, Zhishen ^h   Monberg, Matthew J ^h   Obasaju, Coleman K ^h  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e EARLE A CHILES RESEARCH INSTITUTE   (United States)

^f KAISER PERMANENTE   (United States)

^g PENNSYLVANIA HOSPITAL   (United States)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Chemotherapy naive disease; Compassionate use program; Efficacy; Toxicity

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED; STEROID;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OTOTOXICITY; PANCYTOPENIA; PERITONEUM MESOTHELIOMA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PNEUMONIA; RESPIRATORY FAILURE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 23844441578     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.020     Document Type: Article

References (16)

1. Verschraegen C. Mesothelioma: incidence and survival rates in the United States. Proc Am Soc Clin Oncol 2003; 22:869 (Abstract #3495).
2. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145:211-218.
3. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 1999; 79:666-672.
4. Herndon JE, Green MR, Chahinian AP. et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113:723-731.
5. Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999; 26(2 suppl 6):42-47.
6. Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanism to antifolate drugs. Semin Oncol 1999; 26(2 suppl 6):68-73.
7. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-fine therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92:595-600.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644.
9. Hanna N, Shepherd EA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.
10. Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatement in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
11. Karthaus M, Metzer D, Maher G, et al. Pemetrexed + cisplatin (DDP) in patients with malignant peritoneal mesothelioma (AbM). Proc Am Soc Clin Oncol 2004; 22:663 (Abstract #7201).
12. Deraco M, Kusamura S, Baratti D, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intra peritoneal hyperthermic perfusion: clinical and translational study. Proc Am Soc Clin Oncol 2004; 22:888 (Abstract #9729).
13. Verschraegen C, Le D, Kudelka A, et al. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Proc Am Soc Clin Oncol 2001; 20:90b (Abstract #2110).
14. Topuz E, Eralp Y, Aydiner A, et al. Intraperitoneal chemotherapy in patients with peritoneal malignant mesothelioma. Proc Am Soc Clin Oncol 2001; 20:134b (Abstract #2286).
15. Keohan M, Chabot J, Fountain K, et al. A phase II study of trimodal therapy for peritoneal mesothelioma. Proc Am Soc Clin Oncol 2001; 20:361a (Abstract #1441).
16. Labow D, Coit D, Kelsen D, et al. Primary peritoneal mesothelioma: how aggressive should we be? Proc Am Soc Clin Oncol 2004; 22:345 (Abstract #4132).